高级检索
    周彩存, 黎文锋. 艾乐替尼一线治疗ALK阳性晚期非小细胞肺癌显著优于克唑替尼[J]. 循证医学, 2018, 18(1): 29-32. DOI: 10.12019/j.issn.1671-5144.2018.01.010
    引用本文: 周彩存, 黎文锋. 艾乐替尼一线治疗ALK阳性晚期非小细胞肺癌显著优于克唑替尼[J]. 循证医学, 2018, 18(1): 29-32. DOI: 10.12019/j.issn.1671-5144.2018.01.010
    shu
    ZHOU Cai-cun, LI Wen-feng. Alectinib First-Line Treatment ALK-Positive Advanced Non-Small Cell Lung Cancer Was Significantly Better than Crizotinib[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 29-32. DOI: 10.12019/j.issn.1671-5144.2018.01.010
    Citation: ZHOU Cai-cun, LI Wen-feng. Alectinib First-Line Treatment ALK-Positive Advanced Non-Small Cell Lung Cancer Was Significantly Better than Crizotinib[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 29-32. DOI: 10.12019/j.issn.1671-5144.2018.01.010
    shu

    艾乐替尼一线治疗ALK阳性晚期非小细胞肺癌显著优于克唑替尼

    Alectinib First-Line Treatment ALK-Positive Advanced Non-Small Cell Lung Cancer Was Significantly Better than Crizotinib

      摘要
      • HTML全文
      • 参考文献(9)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回